Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01457)
Name
Talazoparib
Synonyms    Click to Show/Hide the Synonyms of This API
Talazoparib; 1207456-01-6; BMN-673; BMN 673; BMN673; Talzenna; Talazoparib (BMN 673); UNII-9QHX048FRV; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; LT-673; 9QHX048FRV; CHEMBL3137320; 1207456-01-6 (free base); (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; BMN-673 8R,9S; (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; 1207456-00-5; Talazoparib [USAN:INN]; 4pjt; 2YQ; Talazoparib(BMN-673); Talazoparib (USAN/INN); 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-; GTPL8313; SCHEMBL2299348; AOB5705; BMN673,BMN-673; AMY27900; EX-A1356; BDBM50084621; NSC767125; ZINC72318110; ZINC138126699; ACN-053048; CS-0937; DB11760; NSC-767125; QC-4556; SB16478; NCGC00390231-01; AC-30927; AS-57491; HY-16106; LT 00673; S7048; SW219655-1; X5821; D10732; S-7826; Q25100990; Q27453411
Clinical Status
Approved
PubChem CID
135565082
Formula
C19H14F2N6O
Canonical SMILES
CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
InChI
1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
InChIKey
HWGQMRYQVZSGDQ-HZPDHXFCSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135565082"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 380.4 Topological Polar Surface Area 84.2
XlogP 2.3 Complexity 654
Heavy Atom Count 28 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
Full List of Drug Formulations (DFMs) Containing This API
          Talazoparib 0.25 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Silicified Microcrystalline Cellulose (Smcc); Hpmc; Yellow Iron Oxide; Red Iron Oxide; Titanium Dioxide; Shellac; Black Iron Oxide; Potassium Hydroxide; Ammonium Hydroxide; Propylene Glycol
                   Dosage Form Capsule
                   Company Pfizer Laboratories Div Pfizer
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [1]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [2]
          Talazoparib 1 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Silicified Microcrystalline Cellulose (Smcc); Hpmc; Yellow Iron Oxide; Red Iron Oxide; Titanium Dioxide; Shellac; Black Iron Oxide; Potassium Hydroxide; Ammonium Hydroxide; Propylene Glycol
                   Dosage Form Capsule
                   Company Pfizer Laboratories Div Pfizer
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [1]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [2]
References
1 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
2 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.